As swine fever fries China vaccine sales, Boehringer rewrites prescription for recovery
Share:
BEIJING (Reuters) - Germany's Boehringer Ingelheim, the global No. 2 in animal health, is having to rebuild itself in China after a deadly pig disease decimated sales of unrelated mainstay vaccines, bringing write-offs and leaving it facing a three-year slog to recovery.Fresh from launching a brand new vaccine factory in eastern China this year, the privately held company will focus more on larger customers and invest in diagnostics after sales plunged by about 40%, or the same level as the..